Insufficient scRNA-seq data for expression of GBP7 at single-cell level.
Insufficient scRNA-seq data for expression of GBP7 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 1872.59 | 226 / 226 | 81% | 19.89 | 328 / 406 |
adrenal gland | 98% | 81.37 | 253 / 258 | 1% | 0.01 | 2 / 230 |
lung | 93% | 20.93 | 537 / 578 | 1% | 0.03 | 16 / 1155 |
breast | 84% | 8.90 | 384 / 459 | 2% | 0.05 | 22 / 1118 |
thymus | 84% | 6.63 | 548 / 653 | 0% | 0 | 0 / 605 |
brain | 74% | 4.16 | 1964 / 2642 | 6% | 0.11 | 43 / 705 |
kidney | 71% | 5.73 | 63 / 89 | 7% | 0.19 | 65 / 901 |
spleen | 78% | 10.12 | 187 / 241 | 0% | 0 | 0 / 0 |
bladder | 76% | 5.67 | 16 / 21 | 1% | 0.03 | 7 / 504 |
adipose | 76% | 9.63 | 911 / 1204 | 0% | 0 | 0 / 0 |
uterus | 73% | 5.52 | 124 / 170 | 1% | 0.03 | 6 / 459 |
ovary | 71% | 6.45 | 128 / 180 | 0% | 0.01 | 2 / 430 |
prostate | 70% | 5.33 | 172 / 245 | 0% | 0.00 | 1 / 502 |
intestine | 68% | 4.83 | 655 / 966 | 2% | 0.10 | 12 / 527 |
muscle | 70% | 3.60 | 560 / 803 | 0% | 0 | 0 / 0 |
esophagus | 65% | 3.94 | 945 / 1445 | 3% | 0.05 | 5 / 183 |
stomach | 62% | 3.31 | 224 / 359 | 5% | 0.08 | 15 / 286 |
heart | 62% | 3.70 | 537 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 52% | 2.59 | 699 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 50% | 5.05 | 463 / 929 | 0% | 0 | 0 / 0 |
skin | 36% | 1.54 | 646 / 1809 | 11% | 0.48 | 50 / 472 |
pancreas | 28% | 0.87 | 93 / 328 | 1% | 0.06 | 2 / 178 |
eye | 0% | 0 | 0 / 0 | 10% | 0.30 | 8 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051715 | Biological process | cytolysis in another organism |
GO_0034345 | Biological process | negative regulation of type III interferon production |
GO_0051607 | Biological process | defense response to virus |
GO_0043122 | Biological process | regulation of canonical NF-kappaB signal transduction |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0042832 | Biological process | defense response to protozoan |
GO_0046426 | Biological process | negative regulation of receptor signaling pathway via JAK-STAT |
GO_0045070 | Biological process | positive regulation of viral genome replication |
GO_0042742 | Biological process | defense response to bacterium |
GO_0071346 | Biological process | cellular response to type II interferon |
GO_0001818 | Biological process | negative regulation of cytokine production |
GO_0032480 | Biological process | negative regulation of type I interferon production |
GO_0030659 | Cellular component | cytoplasmic vesicle membrane |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0005525 | Molecular function | GTP binding |
GO_0003924 | Molecular function | GTPase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | GBP7 |
Protein name | Guanylate-binding protein 7 (EC 3.6.1.-) (EC 3.6.5.-) (GTP-binding protein 7) (GBP-7) (Guanine nucleotide-binding protein 7) (Guanylate-binding protein 4-like) Guanylate binding protein 7 |
Synonyms | GBP4L |
Description | FUNCTION: Interferon (IFN)-inducible GTPase that plays important roles in innate immunity against a diverse range of bacterial, viral and protozoan pathogens (By similarity). Hydrolyzes GTP to GMP in two consecutive cleavage reactions and predominantly uses GTP and not GDP or GMP as the substrate (By similarity). Following infection, recruited to the pathogen-containing vacuoles or vacuole-escaped bacteria and acts as a positive regulator of inflammasome assembly by promoting the release of inflammasome ligands from bacteria (By similarity). Acts by promoting lysis of pathogen-containing vacuoles, releasing pathogens into the cytosol (By similarity). Following pathogen release in the cytosol, promotes recruitment of proteins that mediate bacterial cytolysis: this liberates ligands that are detected by inflammasomes, such as lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11 inflammasome or double-stranded DNA (dsDNA) that activates the AIM2 inflammasome (By similarity). Also promotes IFN-gamma-mediated host defense against bacterial infections by regulating oxidative responses and bacteriolytic peptide generation (By similarity). May help to assemble NADPH oxidase on phagosomal membranes by acting as a bridging protein between NADPH oxidase cytosolic subunits NCF2-NCF4 and the membrane subunits CYBA-CYBB (By similarity). Participates along with GBP1 in trafficking monoubiquinated protein cargo to autolysosomes for generating ubiquitin-derived antimicrobial peptides (By similarity). Facilitates influenza A virus replication by inhibiting the activation of NF-kappaB and JAK-STAT signaling pathways and the expression of type I, type III interferons and pro-inflammatory cytokines . Confers protection to several pathogens, including the bacterial pathogens Listeria monocytogenes and Mycobacterium bovis BCG as well as the protozoan pathogen Toxoplasma gondii (By similarity). Required for disruption of the parasitophorous vacuole formed following T.gondii infection and subsequent killing of the parasite (By similarity). . |
Accessions | ENST00000650452.1 Q8N8V2 ENST00000294671.3 A0A3B3IRS3 |